Vitrafy Raises Capital to Accelerate U.S. Expansion and Commercialisation
Vitrafy Life Sciences Limited (ASX: VFY) has secured firm commitments for a AU$30 million institutional placement at AU$2.60 per share, reflecting strong support from both new and existing institutional investors. The capital raise follows recent progress in the U.S. blood market, where the company is advancing its cryopreservation platform designed for blood products, animal reproduction, and cell and gene therapy applications. Vitrafy’s ecosystem combines proprietary hardware, software, and consumables, supported by scientific validation, including 94.4% post-thaw platelet recovery demonstrated in U.S. Army studies. The company has also established strategic partnerships with Vitalant and IMV Technologies, strengthening its commercial positioning in key target markets.
Funds raised will primarily support the manufacturing of Guardion devices, expansion of U.S. sales and operations, and general working capital requirements. Eligible shareholders in Australia and New Zealand are expected to be offered participation in a Share Purchase Plan (SPP), providing the company with the potential to secure up to AU$2 million in additional capital on terms aligned with the institutional placement. Management believes the additional capital will support commercial scale-up efforts, regulatory milestones, and growing demand as Vitrafy pursues opportunities across civilian and military blood markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Vitrafy Raises Capital to Accelerate U.S. Expansion and Commercialisation
Vitrafy Life Sciences Limited (ASX: VFY) has secured firm commitments for a AU$30 million institutional placement at AU$2.60 per share, reflecting strong support from both new and existing institutional investors. The capital raise follows recent progress in the U.S. blood market, where the company is advancing its cryopreservation platform designed for blood products, animal reproduction, and cell and gene therapy applications. Vitrafy’s ecosystem combines proprietary hardware, software, and consumables, supported by scientific validation, including 94.4% post-thaw platelet recovery demonstrated in U.S. Army studies. The company has also established strategic partnerships with Vitalant and IMV Technologies, strengthening its commercial positioning in key target markets.
Funds raised will primarily support the manufacturing of Guardion devices, expansion of U.S. sales and operations, and general working capital requirements. Eligible shareholders in Australia and New Zealand are expected to be offered participation in a Share Purchase Plan (SPP), providing the company with the potential to secure up to AU$2 million in additional capital on terms aligned with the institutional placement. Management believes the additional capital will support commercial scale-up efforts, regulatory milestones, and growing demand as Vitrafy pursues opportunities across civilian and military blood markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au